# Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

> **NCT00755118** · PHASE2 · TERMINATED · sponsor: **University Hospital of Crete** · enrollment: 24 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00755118
- **Lead sponsor:** University Hospital of Crete
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Due to poor Accrual
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755118, "Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00755118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*